Share

September 8, 2022

SARS-CoV-2 protein caught severing critical immunity pathway

SARS-CoV-2 protein caught severing critical immunity pathway

Powerful X-rays from SLAC’s synchrotron reveal that our immune system’s primary wiring seems to be no match for a brutal SARS-CoV-2 protein.
By David Krause

Structured Content

Over the past two years, scientists have studied the SARS-CoV-2 virus in great detail, laying the foundation for developing COVID-19 vaccines and antiviral treatments. Now, for the first time, scientists at the Department of Energy’s SLAC National Accelerator Laboratory have seen one of the virus’s most critical interactions, which could help researchers develop more precise treatments.

The team caught the moment when a virus protein, called Mpro, cuts a protective protein, known as NEMO, in an infected person. Without NEMO, an immune system is slower to respond to increasing viral loads or new infections. Seeing how Mpro attacks NEMO at the molecular level could inspire new therapeutic approaches.

To see how Mpro cuts NEMO, researchers funneled powerful X-rays from SLAC’s Stanford Synchrotron Radiation Lightsource (SSRL) onto crystallized samples of the protein complex. The X-rays struck the protein samples, revealing what Mpro looks like when it dismantles NEMO’s primary function of helping our immune system communicate.

“We saw that the virus protein cuts through NEMO as easily as sharp scissors through thin paper,” said co-senior author Soichi Wakatsuki, professor at SLAC and Stanford. “Imagine the bad things that happen when good proteins in our bodies start getting cut into pieces.”

The images from SSRL show the exact location of NEMO’s cut and provide the first structure of SARS-CoV-2 Mpro bound to a human protein.

molecularstructureSARSNEMO.jpg

This image shows how SARS-CoV-2 Mpro recognizes and cuts NEMO based on the crystal structure determined using a powerful X-ray beam at SSRL Beam Line 12-2. (SLAC National Accelerator Laboratory)
This image shows how SARS-CoV-2 Mpro recognizes and cuts NEMO based on the crystal structure determined using a powerful X-ray beam at SSRL Beam Line 12-2. (SLAC National Accelerator Laboratory)

“If you can block the sites where Mpro binds to NEMO, you can stop this cut from happening over and over,” SSRL lead scientist and co-author Irimpan Mathews said. “Stopping Mpro could slow down how fast the virus takes over a body. Solving the crystal structure revealed Mpro’s binding sites and was one of the first steps to stopping the protein.”

The research team from SLAC, DOE’s Oak Ridge National Laboratory, and other institutions published their results today in Nature Communications.

Protecting an immunity pathway

NEMO is part of a human immune system known as the NF-κB pathway. You can think of NEMO and the NF-κB pathway as if they were a card reader and wiring on the outside of a locked building entrance door. If the wires to the card reader are cut, the door will not open, meaning a person (or an immune system activator, like NEMO) is stuck outside, unable to do whatever they came to do.

The NF-κB pathway is a critical part of protective inflammatory responses. When NEMO is cut, our immune response can’t be activated, resulting in various detrimental effects to our body. COVID-19 viral infections could be made worse if Mpro destroys NEMO, helping the virus evade our innate immune responses. Additionally, a separate study by researchers at institutions in Germany found that the loss of NEMO by the action of Mpro could lead to damage in certain brain cells, causing neurological symptoms observed in COVID-19 patients, the researchers said.

3_SARS_NEMO_SSRL_photo.jpg

Researchers stand near SSRL's Beam Line 12-2. From left, Mikhail Hameedi, SLAC scientist and co-first author; Soichi Wakatsuki, co-senior author and professor at SLAC and Stanford; and Irimpan Mathews, SSRL lead scientist and co-author. (Jacqueline Ramseyer Orrell/SLAC National Accelerator Laboratory)

One drug that is currently approved for emergency use targets Mpro proteins by providing an infected person with an Mpro inhibitor. This kind of inhibitor drug could be strengthened now that the location of NEMO’s cut has been observed.

“The crystal structures of NEMO and Mpro provide us with the targets to develop treatments that stop these cuts from happening,” SLAC scientist and co-first author Mikhail Ali Hameedi said. “Although current antiviral drugs can target Mpro, seeing the molecular details of how Mpro attacks NEMO will help us develop new treatments in the future as Mpro mutates.”

Finding ways to improve antiviral inhibitors is especially important with SARS-CoV-2. Among the coronaviruses—a group that includes the original SARS-CoV and MERS‐CoV viruses—SARS-CoV-2’s Mpro is the most effective at attaching to and cutting NEMO. SARS-CoV-2’s Mpro grabs NEMO with a tighter grip than its counterparts in other coronaviruses and could be cutting hundreds of other critical proteins in human host cells, such as those associated with blood disorders, the researchers said.

To predict how well Mpro binds to NEMO, researchers used the Summit supercomputer at the Oak Ridge Leadership Computing Facility. They combined molecular dynamics simulations with five machine learning models in a novel way and applied quantum chemistry, finding that Mpro likely has the highest binding affinity in SARS-CoV-2 compared to the other primary coronaviruses. In previous studies, these techniques helped scientists narrow down a list of potential antiviral inhibitor drugs.

foto_summit.jpg

Oak Ridge National Laboratory scientists Dan Jacobson (left image), a senior author of the paper, and Erica Prates, a co-first author, stand near the Summit supercomputer. (Oak Ridge National Laboratory)

“With a set of computational approaches, we were able to predict the strongest binding spots between NEMO and Mpro,” co-first author and ORNL scientist Erica Prates said. “We think that a high binding affinity at these hot spots helps explain the high fitness of the virus in humans.”

Moving forward, the biomedical industry could use the study to help build better inhibitor drugs and understand how other proteins could be affected by Mpro, Wakatsuki said.

“NEMO is only the tip of the iceberg,” he said. “We can now study what happens when many other proteins in the body are cleaved by Mpro during infection.”

This work was supported by the DOE’s Office of Science, Office of Basic Energy Sciences and the Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences. Additional support came from the National Virtual Biotechnology Laboratory, a group of DOE national laboratories that is focused on responding to COVID-19 pandemic, with funding provided by the Coronavirus CARES Act. SSRL is an Office of Science user facility.

Citation: M. A. Hameedi et al., Nature Communications, 8 September 2022 (10.1038/s41467-022-32922-9)


Press Office Contact: Manuel Gnida, mgnida@slac.stanford.edu, (650) 926-2632


SLAC is a vibrant multiprogram laboratory that explores how the universe works at the biggest, smallest and fastest scales and invents powerful tools used by scientists around the globe. With research spanning particle physics, astrophysics and cosmology, materials, chemistry, bio- and energy sciences and scientific computing, we help solve real-world problems and advance the interests of the nation.

SLAC is operated by Stanford University for the U.S. Department of Energy’s Office of Science. The Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time.